温阳止涕汤治疗肺气虚寒型慢性鼻窦炎的临床研究

徐鑫铭; 蔡纪堂; 李静波; 王俊杰; 吴紫陆

doi:10.14148/j.issn.1672-0482.2022.0109

温阳止涕汤治疗肺气虚寒型慢性鼻窦炎的临床研究

doi: 10.14148/j.issn.1672-0482.2022.0109

1.
河南中医药大学第二临床医学院, 河南郑州 450002
2.
河南省中医院耳鼻喉科, 河南郑州 450002

基金项目:

中医药古籍文献和特色技术传承专项 GZY-KJS-2020-085

河南省中医药科学研究专项 20-21ZY1004

河南省中医药科学研究专项 20-21ZY2206

详细信息

作者简介:
徐鑫铭, 女, 住院医师, E-mail: xuxinming1845@163.com

通讯作者:
蔡纪堂, 男, 教授, 主要从事中医药治疗耳鼻咽喉疾病研究, E-mail: caijitang@163.com

中图分类号: R276.1
计量
- 文章访问数: 205
- HTML全文浏览量: 129
- PDF下载量: 28
- 被引次数: 0
出版历程
- 收稿日期: 2021-08-27
- 网络出版日期: 2022-03-01
- 发布日期: 2022-02-10

Clinical Study on the Treatment of Chronic Sinusitis with Deficiency-Cold of Lung Qi by Wenyang Zhiti Decoction

1.
The Second School of Clinical Medicine, Henan University of Chinese Medicine, Zhengzhou 450002, China
2.
Department of Otolaryngology, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou 450002, China

摘要

摘要: 目的探讨温阳止涕汤治疗肺气虚寒型慢性鼻窦炎的临床疗效及其可能机制。方法 160例肺气虚寒型慢性鼻窦炎患者随机分为对照组和治疗组各80例。对照组给予桉柠蒎肠溶软胶囊和糠酸莫米松鼻喷雾剂，治疗组给予温阳止涕汤局部透药，疗程均为28 d。治疗前后评估2组患者临床疗效、VAS评分、中医证候积分、Lund-Mackay评分、鼻黏膜纤毛清除速度及清除率，ELISA法检测血清炎性因子(IL-17、IL-33、IL-37)及血清免疫调节因子(sTim1、sTim3、sTim4)变化，观察不良反应发生率。结果治疗后，治疗组有效率显著高于对照组(P < 0.01)；2组患者中医证候积分、VAS评分、鼻窦CT Lund-Mackay评分均明显降低(P < 0.05，P < 0.01)，治疗组优于对照组(P < 0.01)；2组患者鼻黏膜纤毛清除速度及清除率均显著增加(P < 0.05，P < 0.01)，治疗组优于对照组(P < 0.01)；2组患者血清IL-17、IL-33、sTim1、sTim3、sTim4均明显降低(P < 0.05，P < 0.01)，治疗组优于对照组(P < 0.01)；2组患者血清IL-37水平均明显升高(P < 0.05，P < 0.01)，治疗组优于对照组(P < 0.01)。2组均未见明显不良反应。结论温阳止涕汤可有效改善肺气虚寒型慢性鼻窦炎患者临床症状，其机制可能与调节血清炎性因子及免疫调节因子水平相关。
- 温阳止涕汤 /
- 慢性鼻窦炎 /
- 肺气虚寒
Abstract: OBJECTIVE To investigate the clinical efficacy and possible mechanism of Wenyang Zhiti Decoction in the treatment of chronic sinusitis with deficiency-cold of lung qi. METHODS A total of 160 patients with chronic sinusitis with deficiency-cold of lung qi were randomly divided into the control group and the treatment group of 80 patients each. In the control group, enteric soft capsule and mometasone furoate nasal spray were administered. While in the treatment group, Wenyang Zhiti Decoction was given as local administration of drugs. The course of treatment was 28 days. In addition, the clinical efficacy, VAS score, traditional Chinese medicine (TCM) syndrome score, Lund-Mackay score, as well as nasal mucosal cilia clearance speed and rate of the two groups were evaluated before and after treatment. The changes of serum inflammatory factors (IL-17, IL-33, IL-37) and serum immunomodulatory factors (sTim1, sTim3, sTim4) were detected by ELISA to observe the incidence of adverse reactions. RESULTS After treatment, the efficiency of the treatment group was significantly increased than that of the control group (P < 0.01). The TCM syndrome score, VAS score and Lund-Mackay score of sinus CT were significantly reduced in both groups (P < 0.05, P < 0.01), but the Results in the treatment group were better than those in the control group (P < 0.01). In addition, the clearance speed and rate of nasal mucous membrane cilia were significantly increased in both groups (P < 0.05, P < 0.01), but the Results in the treatment group were better than those in the control group (P < 0.01). Besides, the serum IL-17, IL-33, sTim1, sTim3 and sTim4 were significantly reduced in both groups (P < 0.05, P < 0.01), but the Results in the treatment group were better than those in the control group (P < 0.01). The serum IL-37 level was significantly increased in both groups (P < 0.05, P < 0.01), but the result in the treatment group was better than that in the control group (P < 0.01). In addition, no significant adverse effects were observed in both groups. CONCLUSION Wenyang Zhiti Decoction can effectively improve the clinical symptoms of patients with chronic sinusitis with deficiency-cold of lung qi, and its mechanism may be related to the regulation of serum inflammatory factors and immunomodulatory factors.
- Wenyang Zhiti Decoction /
- chronic sinusitis /
- deficiency-cold of lung qi

HTML全文

表 1 2组患者临床疗效比较

Table 1. Comparison of the clinical efficacy between the 2 groups

组别	例数	完全控制	部分控制	无效	有效率/%
治疗组	78	48	26	4	94.80^##
对照组	76	15	42	19	75.00
注: 组间比较, χ²=11.96, ^##P < 0.01。

下载: 导出CSV

表 2 2组患者治疗前后VAS评分比较(x±s)

Table 2. Comparison of the VAS scores before and after treatment between the 2 groups (x±s)

组别	例数	治疗前	治疗后
治疗组	78	7.10±1.13	1.42±0.59^**##
对照组	76	7.16±1.35	3.91±0.94^**
注: 组内比较, ^**P < 0.01;组间比较, ^##P < 0.01。

下载: 导出CSV

表 3 2组患者治疗前后中医证候积分比较(x±s)

Table 3. Comparison of the TCM syndrome scores before and after treatment between the 2 groups (x±s)

组别	时间	例数	鼻塞	黏白涕	嗅觉减退	气短乏力	自汗畏风	总评分
治疗组	治疗前	78	1.46±0.86	1.56±0.68	1.54±0.88	1.43±0.67	1.56±0.79	7.88±1.46
治疗组	治疗后	78	0.53±0.64^**##	0.52±0.58^**##	0.52±0.76^**##	0.43±0.59^**##	0.55±0.72^**##	2.63±0.98^**##
对照组	治疗前	76	1.52±0.93	1.47±0.77	1.53±0.94	1.38±0.49	1.42±0.81	8.02±1.78
对照组	治疗后	76	1.03±0.85^*	0.96±0.83^*	1.04±0.73^*	0.93±0.82^*	1.02±0.75^*	5.01±1.46^*
注: 组内比较, ^P < 0.05, ^*P < 0.01;组间比较, ^##P < 0.01。

下载: 导出CSV

表 4 2组患者治疗前后Lund-Mackay评分比较(x±s)

Table 4. Comparison of the Lund-Mackay scores before and after treatment between the 2 groups (x±s)

组别	例数	治疗前	治疗后
治疗组	78	18.86±1.82	3.99±0.81^**##
对照组	76	17.87±2.02	9.03±1.13^**
注: 组内比较, ^**P < 0.01;组间比较, ^##P < 0.01。

下载: 导出CSV

表 5 2组患者治疗前后糖精试验结果比较(x±s)

Table 5. Comparison of saccharin test results before and after treatment between the 2 groups (x±s)

组别	时间	例数	纤毛清除速度/(mm·min^-1)	纤毛清除率/%
治疗组	治疗前	78	3.64±0.74	41.21±4.03
治疗组	治疗后	78	7.26±0.85^**##	86.56±7.89^**##
对照组	治疗前	76	3.52±0.67	44.54±2.03
对照组	治疗后	76	4.25±0.77^*	54.22±2.51^*
注: 组内比较, ^P < 0.05, ^*P < 0.01;组间比较, ^##P < 0.01。

下载: 导出CSV

表 6 2组患者治疗前后血清炎性因子水平比较(x±s, pg · mL^-1)

Table 6. Comparison of the serum inflammatory factor levels before and after treatment between the 2 groups (x±s, pg · mL^-1)

组别	时间	例数	IL-17	IL-33	IL-37
治疗组	治疗前	78	223.43±32.63	243.72±30.42	76.24±10.81
治疗组	治疗后	78	95.23±20.98^**##	91.56±18.22^**##	152.02±20.30^**##
对照组	治疗前	76	214.81±42.37	227.63±31.48	75.89±12.68
对照组	治疗后	76	173.12±26.02^*	168.43±22.74^*	93.65±18.41^*
注: 组内比较, ^P < 0.05, ^*P < 0.01;组间比较, ^##P < 0.01。

下载: 导出CSV

表 7 2组患者治疗前后血清免疫调节因子水平比较(x±s, ng · mL^-1)

Table 7. Comparison of the serum immunomodulators before and after treatment between the 2 groups (x±s, ng · mL^-1)

组别	时间	例数	sTim1	sTim3	sTim4
治疗组	治疗前	78	10.21±1.49	11.42±1.32	9.63±0.88
治疗组	治疗后	78	3.42±0.63^**##	3.06±0.31^**##	3.22±0.36^**##
对照组	治疗前	76	9.89±0.99	10.75±1.71	10.11±1.44
对照组	治疗后	76	7.64±0.83^*	7.42±1.37^*	6.56±0.76^*
注: 组内比较, ^P < 0.05, ^*P < 0.01;组间比较, ^##P < 0.01。

下载: 导出CSV

参考文献(27)

[1]	蒋子涵, 孟娟. 慢性鼻窦炎内在型研究进展[J]. 临床耳鼻咽喉头颈外科杂志, 2020, 34(1): 13-18. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH202001004.htm JIANG ZH, MENG J. Advances in the endotypes of chronic rhinosinusitis[J]. J Clin Otorhinolaryngol Head Neck Surg, 2020, 34(1): 13-18. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH202001004.htm
[2]	中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 中国慢性鼻窦炎诊断和治疗指南(2018)[J]. 中华耳鼻咽喉头颈外科杂志, 2019, 54(2): 81-100. doi: 10.3760/cma.j.issn.1673-0860.2019.02.001 Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery, Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chinese Guidelines for diagnosis and treatment of chronic sinusitis (2018)[J]. Chin J Otorhinolaryngol Head Neck Surg, 2019, 54(2): 81-100. doi: 10.3760/cma.j.issn.1673-0860.2019.02.001
[3]	付清玲, 史剑波. 我国慢性鼻-鼻窦炎的流行病学特征及其伴随疾病和危险因素解析[J]. 临床耳鼻咽喉头颈外科杂志, 2018, 32(5): 321-324. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH201805001.htm FU QL, SHI JB. Epidemiology, occupational and environmental risk factors of chronic rhinosinusitis in China[J]. J Clin Otorhinolaryngol Head Neck Surg, 2018, 32(5): 321-324. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH201805001.htm
[4]	刘江怡, 廖敏, 李双, 等. 鼻黏膜上皮在慢性鼻窦炎鼻息肉发病中的作用研究进展[J]. 中国中西医结合耳鼻咽喉科杂志, 2020, 28(6): 477-480. https://www.cnki.com.cn/Article/CJFDTOTAL-XYJH202006021.htm LIU JY, LIAO M, LI S, et al. Advances in research on the role of nasal mucosa epithelium in the pathogenesis of chronic sinusitis and nasal polyps[J]. Chin J Otorhinolaryngol Integr Med, 2020, 28(6): 477-480. https://www.cnki.com.cn/Article/CJFDTOTAL-XYJH202006021.htm
[5]	宋晓, 赵松奇, 黄俊杰. 温肺止流丹加减联合糠酸莫米松鼻喷剂治疗慢性鼻-鼻窦炎的疗效及安全性[J]. 中国实用医刊, 2021, 48(3): 106-109. doi: 10.3760/cma.j.cn115689-20201023-05000 SONG X, ZHAO SQ, HUANG JJ. Effect and safety of modified Wenfei Zhiliu pellet combined with mometasone furoate nasal spray in the treatment of chronic rhinosinusitis[J]. Chin J Tradit Med Sci Technol, 2021, 48(3): 106-109. doi: 10.3760/cma.j.cn115689-20201023-05000
[6]	佘靖. 蔡福养[M]. 北京: 中国中医药出版社, 2007: 144-145. SHE J. Cai Fuyang[M]. Beijing: China press of traditional Chinese medicine, 2007: 144-145.
[7]	刘蓬. 中医耳鼻咽喉科学[M]. 北京: 中国中医药出版社, 2016: 111-114. LIU P. Otorhinolaryngology of TCM[M]. Beijing: China press of traditional Chinese medicine, 2016: 111-114.
[8]	中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 慢性鼻-鼻窦炎诊断和治疗指南(2012年, 昆明)[J]. 中华耳鼻咽喉头颈外科杂志, 2013, 48(2): 92-94. doi: 10.3760/cma.j.issn.1673-0860.2013.02.002 Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery, Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chronic rhinosinusitis diagnosis and treatment guidelines (2012, Kunming)[J]. Chin J Otorhinolaryngol Head Neck Surg, 2013, 48(2): 92-94. doi: 10.3760/cma.j.issn.1673-0860.2013.02.002
[9]	LUND VJ, MACKAY IS. Staging in rhinosinusitis[J]. Rhinology, 1993, 31(4): 183-184.
[10]	冶娟, 王菲. 枸地氯雷他定联合鼻窦内窥镜手术治疗慢性鼻窦炎疗效及对患者血清TIgE、ECP和炎性因子的影响[J]. 中国内镜杂志, 2017, 23(2): 21-25. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGNJ201702006.htm YE J, WANG F. Curative efficacy of desloratadine citrate disodium in combination with endoscopic sinus surgery and its effects on serum TIgE, ECP and inflammatory factors in patients with chronic sinusitis[J]. China J Endosc, 2017, 23(2): 21-25. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGNJ201702006.htm
[11]	李艳青, 张重华, 臧朝平. 中药熏蒸联合"逐渊汤"治疗慢性鼻窦炎的临床疗效研究[J]. 临床耳鼻咽喉头颈外科杂志, 2020, 34(1): 5-9. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH202001002.htm LI YQ, ZHANG CH, ZANG CP. Clinical study of Chinese medicine fumigation combined with "Zhuyuan Decoction" in the treatment of chronic sinusitis[J]. J Clin Otorhinolaryngol Head Neck Surg, 2020, 34(1): 5-9. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH202001002.htm
[12]	王彦, 黄少鹏, 郑昊, 等. 慢性鼻窦炎伴鼻息肉患者嗅觉障碍严重程度的影响因素分析[J]. 中国耳鼻咽喉头颈外科, 2021, 28(10): 599-602. https://www.cnki.com.cn/Article/CJFDTOTAL-EBYT202110002.htm WANG Y, HUANG SP, ZHENG H, et al. Analysis of influence factors for olfactory dysfunctions in patients with chronic rhinosinusitis with nasal polyps[J]. Chin Arch Otolaryngol Head Neck Surg, 2021, 28(10): 599-602. https://www.cnki.com.cn/Article/CJFDTOTAL-EBYT202110002.htm
[13]	王敏, 任海棠, 张劲, 等. 非侵袭性真菌性鼻-鼻窦炎患者免疫指标研究[J]. 中华医院感染学杂志, 2020, 30(5): 725-728. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY202005021.htm WANG M, REN HT, ZHANG J, et al. Changes of immune indexes of patients with non-invasive fungal rhinosinusitis[J]. Chin J Nosocomiology, 2020, 30(5): 725-728. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY202005021.htm
[14]	杨东琴, 张玉梅, 吴凌云, 等. Tim3/galectin-9在血液系统肿瘤中的研究进展[J]. 中国实验血液学杂志, 2021, 29(4): 1360-1364. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY202104058.htm YANG DQ, ZHANG YM, WU LY, et al. Research progress in the role of Tim3/galectin-9 in hematological malignancy[J]. J Exp Hematol, 2021, 29(4): 1360-1364. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY202104058.htm
[15]	WOLF Y, ANDERSON AC, KUCHROO VK. TIM3 comes of age as an inhibitory receptor[J]. Nat Rev Immunol, 2020, 20(3): 173-185. doi: 10.1038/s41577-019-0224-6
[16]	PATEL R, KIM K, SHUTINOSKI B, et al. Culling of APCs by inflammatory cell death pathways restricts TIM3 and PD-1 expression and promotes the survival of primed CD8 T cells[J]. Cell Death Differ, 2017, 24(11): 1900-1911. doi: 10.1038/cdd.2017.112
[17]	CHEN M, WANG L, WANG YG, et al. Soluble Tim3 detection by time-resolved fluorescence immunoassay and its application in membranous nephropathy[J]. J Clin Lab Anal, 2020, 34(6): 23248.
[18]	BARLOW JL, WONG SH, BALLANTYNE SJ, et al. Tim1 and Tim3 are not essential for experimental allergic asthma[J]. Clin Exp Allergy, 2011, 41(7): 1012-1021. doi: 10.1111/j.1365-2222.2011.03728.x
[19]	王新亭, 郑鹏远, 罗予, 等. TIM1与TIM4对小鼠食物过敏模型中CD4⁺CD25⁺调节性T细胞功能的影响[J]. 世界华人消化杂志, 2009, 17(34): 3507-3513. doi: 10.3969/j.issn.1009-3079.2009.34.007 WANG XT, ZHENG PY, LUO Y, et al. TIM4 and TIM1 modulate the function of CD4⁺CD25⁺T regulatory cells in mice with food allergy[J]. World Chin J Dig, 2009, 17(34): 3507-3513. doi: 10.3969/j.issn.1009-3079.2009.34.007
[20]	HU TY, FAN XQ, MA L, et al. TIM4-TIM1 interaction modulates Th2 pattern inflammation through enhancing SIRT1 expression[J]. Int J Mol Med, 2017, 40(5): 1504-1510. doi: 10.3892/ijmm.2017.3150
[21]	刘洋, 王新有, 王秀娟, 等. ITP患者血清中可溶性Tim3/Galectin9水平及其临床意义[J]. 免疫学杂志, 2019, 35(9): 799-804. https://www.cnki.com.cn/Article/CJFDTOTAL-MYXZ201909013.htm LIU Y, WANG XY, WANG XJ, et al. The level and clinical significance of soluble Tim3/Galectin9 in serum of primary immune thrombocytopenia patients[J]. Immunol J, 2019, 35(9): 799-804. https://www.cnki.com.cn/Article/CJFDTOTAL-MYXZ201909013.htm
[22]	王重阳, 金海南, 刘思奇, 等. IL-17A通过p38 MAPK/ERK1/2信号通路上调慢性鼻窦炎患者MMP-9的表达[J]. 中国病理生理杂志, 2021, 37(11): 2031-2037. doi: 10.3969/j.issn.1000-4718.2021.11.015 WANG CY, JIN HN, LIU SQ, et al. IL-17A up-regulates expression of MMP-9 in patients with chronic rhinosinusitis through p38 MAPK/ERK1/2 signaling pathway[J]. Chin J Pathophysiol, 2021, 37(11): 2031-2037. doi: 10.3969/j.issn.1000-4718.2021.11.015
[23]	蔡佳玉, 卢红艳, 苏兆亮, 等. 支气管肺发育不良小鼠肺组织3型固有淋巴细胞(ILC3)数量及相关细胞因子IL-17和IL-22分泌增加[J]. 细胞与分子免疫学杂志, 2020, 36(10): 865-870. https://www.cnki.com.cn/Article/CJFDTOTAL-XBFM202010001.htm CAI JY, LU HY, SU ZL, et al. The number of ILC3 and their related cytokines IL-17 and IL-22 increase in lungs of mice with bronchopulmonary dysplasia[J]. Chin J Cell Mol Immunol, 2020, 36(10): 865-870. https://www.cnki.com.cn/Article/CJFDTOTAL-XBFM202010001.htm
[24]	林洁如, 张湘燕, 彭春红. IL-33/ST2信号通路在肺炎中的研究进展[J]. 医学研究生学报, 2017, 30(12): 1332-1335. https://www.cnki.com.cn/Article/CJFDTOTAL-JLYB201712022.htm LIN JR, ZHANG XY, PENG CH. The role of the IL-33/ST2 axis in pneumonia[J]. J Med Postgrad, 2017, 30(12): 1332-1335. https://www.cnki.com.cn/Article/CJFDTOTAL-JLYB201712022.htm
[25]	LIU XS, WU ZY, CHEN S, et al. A single nucleotide polymorphism in the IL1RL1 gene is associated with Behcet's disease in a Chinese Han population[J]. Int J Ophthalmol, 2021, 14(9): 1315-1320. doi: 10.18240/ijo.2021.09.04
[26]	HU DJ. Role of anti-inflammatory cytokines IL-35 and IL-37 in asthma[J]. Inflammation, 2017, 40(2): 697-707. doi: 10.1007/s10753-016-0480-6
[27]	WANG HZ, ZHANG YJ, LUOMEI JZ, et al. The miR-155/GATA3/IL37 axis modulates the production of proinflammatory cytokines upon TNF-α stimulation to affect psoriasis development[J]. Exp Dermatol, 2020, 29(7): 647-658. doi: 10.1111/exd.14117